Search Videos by Topic or Participant
Browse by Series:

Role of Genetic Testing in Breast Cancer

Discussant: Francisco J. Esteva, MD, PhD, NYU
Published Online: Friday, Mar 20, 2015
For High-Definition, Click
The paradigm in breast cancer has changed from a purely histopathological diagnosis to a more genomic-based or molecular-based focus, Francisco J. Esteva, MD, PhD, states. Treatments are now based on information beyond just the architecture of the cancer to examine which proteins are expressed (eg, estrogen receptor, progesterone receptor, HER2, etc.).

Several multigene panel tests can be used to delve deeper into the genomic profiling of a patient’s cancer, including Oncotype DX, Mammaprint, and Prosigna, Esteva explains. These tests can be used to categorize patients into low-, intermediate- and high-risk groups, which in turn can determine a patient’s potential benefit from chemotherapy versus targeted therapy.
Slider Left
Slider Right
For High-Definition, Click
The paradigm in breast cancer has changed from a purely histopathological diagnosis to a more genomic-based or molecular-based focus, Francisco J. Esteva, MD, PhD, states. Treatments are now based on information beyond just the architecture of the cancer to examine which proteins are expressed (eg, estrogen receptor, progesterone receptor, HER2, etc.).

Several multigene panel tests can be used to delve deeper into the genomic profiling of a patient’s cancer, including Oncotype DX, Mammaprint, and Prosigna, Esteva explains. These tests can be used to categorize patients into low-, intermediate- and high-risk groups, which in turn can determine a patient’s potential benefit from chemotherapy versus targeted therapy.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x